Improving outcomes of percutaneous coronary intervention through the application of guidelines and benchmarking: Reduction of major bleeding and blood transfusion as a model

Clinical Cardiology

Volumn 30, Issue 10 SUPPL., 2007, Pages II-44-II-48

  Chetcuti, Stanley J ^a   Grossman, Paul M ^a   Kline Rogers, Eva M ^a   Montoye, Cecelia ^b   Smith, Dean ^a   Moscucci, Mauro ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b ST JOSEPH MERCY HOSPITAL   (United States)

Author keywords

Bleeding; Ischemia; Quality improvement; Transfusion

Indexed keywords

BLEEDING; BLOOD TRANSFUSION; HUMAN; MODEL; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; QUALITY CONTROL; REVIEW; RISK FACTOR; TOTAL QUALITY MANAGEMENT;

EID: 35348830501     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20230     Document Type: Review

References (24)

1. Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, et al.: Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction, Phase II Trial. Ann Intern Med 1991;115:256-265
2. Bovill EG, Tracy RP, Knatterud GL, Stone PH, Nasmith J, et al.: Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina Thrombolysis in Myocardial Ischemia, phase IIIB trial. Am J Cardiol 1997;79:391-396
3. Tcheng JE: Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: Bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J 2000;139(2):S38-S45
4. Moscucci M, Rogers EK, Montoye C, Smith DE, Share D, et al.: Association of a continuous quality improvement initiative with practice and outcome variations of contemporary percutaneous coronary interventions. Circulation 2006;113:814-822
5. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ: The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996;334:1685-1690
6. Alter HJ, Nakatsuji Y, Melpolder J, Wages J, Wesley R, et al.: The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. N Engl J Med 1997;336:747-754
7. Moscucci M, Fox KA, Cannon CP, Klein W, López-Sendón J, et al.: Predictors of major bleeding in acute coronary syndromes: The Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003;24:1815-1823
8. Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, et al.: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999;340:409-417
9. Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, et al.: Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004;292:1555-1562
10. Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, et al.: Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003;92:930-935
11. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP: Transfusion medicine. First of two parts-blood transfusion. N Engl J Med 1999;340:438-447
12. Gong MN, Thompson BT, Williams P, Pothier L, Boyce PD, et al.: Clinical predictors of and mortality in acute respiratory distress syndrome: Potential role of red cell transfusion. Crit Care Med 2005;33:1191-1198
13. Taylor RW, Manganaro L, O'Brien J, Trottier SJ, Parker N, et al.: Impact of allogenic packed red blood cell transfusion on nosocomial infection rates in the critically ill patient. Crit Care Med 2002;30:2249-2254
14. Moscucci M, Mansour KA, Kent KC, Kuntz RE, Senerchia C, et al.: Peripheral vascular complications of directional coronary atherectomy and stenting: Predictors, management, and outcome. Am J Cardiol 1994;74:448-453
15. Popma JJ, Satler LF, Pichard AD, Kent KM, Campbell A, et al.: Vascular complications after balloon and new device angioplasty. Circulation 1993;88:1569-1578
16. Schiller GJ, Berkman SA: Hematologic aspects of renal insufficiency. Blood Rev 1989;3:141-146
17. Follea G, Laville M, Pozet N, Dechavanne M: Pharmacokinetic studies of standard heparin and low molecular weight heparin in patients with chronic renal failure. Haemostasis 1986;16:147-151
18. Hory B, Claudet MH, Magnette J, Bechtel P, Bayrou B: Pharmacokinetic of a very low molecular weight heparin in chronic renal failure. Thromb Res 1991;63:311-317
19. Moscucci M, Share D, Smith D, O'Donnell MJ, Riba A, et al.: Relationship between operator volume and adverse outcome in contemporary percutaneous coronary intervention practice: An analysis of a quality-controlled multicenter percutaneous coronary intervention clinical database. J Am Coll Cardiol 2005;46:625-632
20. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, et al., REPLACE-2 Investigators: Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-863
21. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, et al., ACUITY Investigators: Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-2216
22. American College of Physicians: Practice strategies for elective red blood cell transfusion. Ann Intern Med 1992;116 403-406
23. Moscucci M, Ricciardi M, Eagle KA, Kline E, Bates ER, et al.: Frequency, predictors, and appropriateness of blood transfusion after percutaneous coronary interventions. Am J Cardiol 1998;81:702-707
24. Ghali WA, Palepu A, Paterson WG: Evaluation of red blood cell transfusion practices with the use of preset criteria. CMAJ 1994;150:1449-1454